摘要
目的探讨脱氧核苷酸联合聚乙二醇化干扰素α-2a治疗慢性乙型病毒性肝炎合并肝功能异常的临床效果。方法将慢性乙型病毒性肝炎合并肝功能异常患者78例随机分为两组,对照组39例采用聚乙二醇化干扰素α-2a治疗,观察组39例采用脱氧核苷酸联合聚乙二醇化干扰素α-2a治疗,比较两组治疗效果。结果治疗后,两组丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、总胆红素、碱性磷酸酶、白蛋白、总蛋白、白细胞计数、血小板计数降低(P<0.05),肝组织炎性程度、纤维化程度改善(P<0.05)。观察组丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、总胆红素、碱性磷酸酶低于对照组(P<0.05),白蛋白、总蛋白、白细胞计数、血小板计数、HBe Ag阴转率、HBVDNA阴转率、HBs Ag阴转率高于对照组(P<0.05),肝组织炎性程度、纤维化程度好于对照组(P<0.05)。结论脱氧核苷酸联合聚乙二醇化干扰素α-2a治疗慢性乙型病毒性肝炎合并肝功能异常的疗效显著,可明显改善临床指标,减轻肝组织炎性程度与纤维化程度。
Objective To explore the clinical curative effect of deoxynucleotide combined with peginterferonα-2a in treatment of chronic hepatitis B with abnormal liver function. Methods 78 patients with chronic hepatitis B and abnormal liver function were randomly divided into the control group and the observation group. 39 patients in the control group were treated by peginterferonα-2a while 39 patients in the observation group were treated by deoxynucleotide combined with peginterferonα-2a. Curative effects of two groups were compared. Results After treatment, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein, white blood cell count, platelet count of two groups were decreased（P〈0.05）. Inflammation degree and fibrosis degree of liver tissue were improved（P〈0.05）. Alanine aminotransferase, aspartate aminotransferase, total bilirubin and alkaline phosphatase of the observation group were lower than those of the control group（P〈0.05）.But albumin, total protein, white blood cell count, platelet count, HBe Ag negative conversion rate, HBVDNA negative conversion rate, HBs Ag negative conversion rate of the observation group were higher than those of the control group（P〈0.05）. Inflammation degree and fibrosis degree of liver tissue of the observation group were better than those of the control group（P〈0.05）. Conclusion Deoxynucleotide combined with peginterferonα-2a in treatment of chronic hepatitis B with abnormal liver function has significant curative effect. In addition, it can improve significantly improve clinical indicators and reduce inflammation degree and fibrosis degree of liver tissue.
出处
《中国医药科学》
2016年第5期100-103,共4页
China Medicine And Pharmacy
